BTK Inhibitors in CLL: Second Generation Drugs and Beyond
May 30th 2024Dr. Constantine Tam provides an overview of the current and emerging treatment landscape for chronic lymphocytic leukemia (CLL), with a focus on Bruton's tyrosine kinase (BTK) inhibitors like ibrutinib and the next generation of BTK inhibitors under development.
Read More